SPRING HOUSE, Pa. — Johnson & Johnson (NYSE: JNJ) today announced new findings on IMAAVY® (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG) across 15 novel abstracts to be presented at the 2026 Myasthenia Gravis Foundation of America (MGFA) Scientific Session and American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual...

Indianapolis, Indiana – The next-generation triple-combination CFTR modulator Alyftrek has demonstrated a favorable safety profile and improved CFTR function in children with cystic fibrosis (CF) as young as 2, according to findings from a Phase 3 clinical trial. The study, known as TIMBERLINE (NCT05422222), also found that children who switched...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, will present new data from across its portfolio and pipeline at the 2026 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and the Myasthenia Gravis Foundation of America (MGFA) Scientific Session in Orlando,...